Sage Therapeutics
SAGE
SAGE was delisted on the 30th of July, 2025.
272 hedge funds and large institutions have $10.6B invested in Sage Therapeutics in 2019 Q2 according to their latest regulatory filings, with 44 funds opening new positions, 99 increasing their positions, 83 reducing their positions, and 33 closing their positions.
33% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 33
19% more repeat investments, than reductions
Existing positions increased: 99 | Existing positions reduced: 83
19% more capital invested
Capital invested by funds: $8.95B → $10.6B (+$1.68B)
3.04% more ownership
Funds ownership: 110.53% → 113.57% (+3%)
2% more funds holding
Funds holding: 267 → 272 (+5)
30% less funds holding in top 10
Funds holding in top 10: 10 → 7 (-3)
36% less call options, than puts
Call options by funds: $103M | Put options by funds: $162M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$536M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$229M |
| 3 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$223M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$106M |
| 5 |
Jennison Associates
New York
|
+$102M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MWNA
Marshall Wace North America
New York
|
-$70.7M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$69.9M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$61.1M |
| 4 |
Bank of New York Mellon
New York
|
-$46.2M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$27M |
SAGE Hedge Fund Activity: Q2 2019 in Review
272 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q2 2019, worth a combined $10.6B — up 19% from $8.95B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new SAGE positions and 33 closed out — a net gain of 11 holders — while 99 added to existing stakes and 83 trimmed.
The largest buyer was Capital International Investors, opening a new position worth an estimated $536M. The largest seller was Marshall Wace North America, cutting an estimated $70.7M.
- 272 institutional investors held Sage Therapeutics (SAGE) as of Q2 2019, up from 267 in Q1 2019.
- Funds reported $10.6B of Sage Therapeutics stock for Q2 2019, up 19% quarter-over-quarter.
- 44 funds opened new Sage Therapeutics positions in Q2 2019 and 33 closed out, a net change of +11 holders.
- The largest Sage Therapeutics buyer in Q2 2019 was Capital International Investors, an estimated $536M added.
- The largest Sage Therapeutics seller in Q2 2019 was Marshall Wace North America, an estimated $70.7M sold.
Based on aggregated 13F filings for Q2 2019.